Skip to main content

Day: September 4, 2024

VGP’s ‘BBB-’ Credit Rating Reaffirmed by Fitch Ratings

PRESS RELEASE Regulated Information Antwerp, Belgium, 4 September 2024 (07.00 a.m. CET) VGP NV (‘VGP’ or ‘the Group’), a European provider of high-quality logistics and semi-industrial real estate, has had its credit rating reaffirmed by the Rating Agency Fitch Ratings (‘Fitch’). Fitch has reaffirmed the credit rating for VGP NV with a Long-Term Issuer Default Rating (IDR) and senior unsecured rating at ‘BBB-‘. The Outlook on the rating is Stable. Fitch stated: “The ratings reflect VGP’s continued discipline in managing development risk, from land location and price, the quality of units built, pre-lets, its development profit headroom, to completion when new properties are sold to pre-funded dedicated 50-50 joint ventures (JVs).” For further details and the full rating report please refer to the Fitch corresponding press...

Continue reading

Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Geneva, Switzerland, September 4, 2024 – Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that CEO, Tim Dyer, will be attending the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9 – 11, 2024, at the Lotte New York Palace Hotel. A pre-recorded video presentation by Mr. Dyer in which he provides a corporate update and discusses recent developments at Addex, will be available for viewing on-demand from 07:00 EDT on Monday, September 9, 2024, via the following webcast link. Mr. Dyer will be available for one-on-one meetings throughout the conference. For more information or to schedule a meeting, please contact IR@addexpharma.com. About Addex:Addex...

Continue reading

Pharming Group to participate in September investor conferences

Leiden, the Netherlands, September 4, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conferences in the U.S. in the month of September:2024 Wells Fargo Healthcare Conference, Boston, September 4-6Sijmen de Vries, Chief Executive Officer, will participate in a fireside chat question and answer session on Friday, September 6 at 08:45 AM ET/14:45 CET. A live webcast and replay of the presentation will be available in the “Upcoming Events” and “News” sections of Pharming’s website. H.C. Wainwright 26th Annual Global Investment Conference, New York, September 9-11Sijmen de Vries, Chief Executive Officer, will present on Monday, September 9 at 10:30 AM ET/16:30 CET. A live webcast and replay of the presentation will be available...

Continue reading

Canacol Energy Ltd. Announces the Closing of a US $75 Million Senior Secured Term Loan

CALGARY, Alberta, Sept. 03, 2024 (GLOBE NEWSWIRE) — Canacol Energy Ltd. (“Canacol” or the “Corporation”) (TSX: CNE; OTCQX: CNNEF; BVC: CNEC) is pleased to announce that, on September 3, 2024, it entered into a committed 24 month US $75 million senior secured term loan facility (the “Facility”) with Macquarie Group (“Macquarie”). The initial draw on funding is expected to be US $50 million, with a further commitment of US $25 million available for a twelve month period should certain production metrics be met. The Facility bears an annual interest rate of SOFR + 8.0% on drawn amounts and 2.4% on undrawn amounts during the commitment period. The Corporation expects to enter a SOFR hedging agreement with Macquarie fixing the interest rate. The Facility matures on September 3, 2026, and has a twelve month principal payment grace period....

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.